GSK: licenses tuberculosis vaccine candidate
(CercleFinance.com) - GSK has announced the license of its tuberculosis vaccine candidate M72/AS01 to the Gates MRI.
In a phase IIb trial this tuberculosis vaccine candidate demonstrated the potential to halve active pulmonary tuberculosis in adults suffering from a latent tuberculosis infection.
"The licensing agreement is a significant step forward to continue the development of the vaccine candidate for low-income countries with high TB burdens," GSK said.
Dr. Thomas Breuer, Chief Medical Officer of GSK Vaccines, said, "At GSK, we are very proud to have developed a TB vaccine candidate which has shown promising clinical trial results in adolescents and adults where the need to combat the TB epidemic is greatest."
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In a phase IIb trial this tuberculosis vaccine candidate demonstrated the potential to halve active pulmonary tuberculosis in adults suffering from a latent tuberculosis infection.
"The licensing agreement is a significant step forward to continue the development of the vaccine candidate for low-income countries with high TB burdens," GSK said.
Dr. Thomas Breuer, Chief Medical Officer of GSK Vaccines, said, "At GSK, we are very proud to have developed a TB vaccine candidate which has shown promising clinical trial results in adolescents and adults where the need to combat the TB epidemic is greatest."
Copyright (c) 2020 CercleFinance.com. All rights reserved.